AVANOS MEDICAL, INC.(AVNS)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-03-31.

AVANOS MEDICAL, INC. (AVNS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVNS at 36.1/100 on a 32-signal composite quality model, placing it at rank #2,282 of 2,961 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (15.8) and balance sheet strength (20.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 42.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AVANOS MEDICAL, INC. reports quarterly revenue of $182.2M, net income of $5.1M, free cash flow of $-16.6M. Top institutional holders of AVNS by reported 13-F value include BlackRock, NEXPOINT ASSET MANAGEMENT, L.P., STATE STREET, based on the most recent SEC filings. AVNS trades on the NYSE exchange and files with the SEC under CIK 1606498. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVNS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVANOS MEDICAL, INC. directly from SEC EDGAR.